TG Therapeutics: 3 Key Takeaways for Long-Term Investors

TG Therapeutics (TGTX) delivered a strong third-quarter 2026 earnings call, boosting investor confidence in its long-term outlook. The main takeaways from the presentation are:

1. Revenue Guidance: TG Therapeutics raised its full-year 2026 global revenue guidance to $1 billion, driven by the expanding adoption of its intravenous antibody therapy BRIUMVI for relapsing multiple sclerosis. The company's operating cash flow from BRIUMVI commercial momentum provides funding for pipeline expansion. The CFO highlighted the $915 million to $920 million full-year revenue outlook for U.S. BRIUMVI net product revenue and the total global revenue, including payments from the ex-U.S. partner.

2. Commercial Expansion: Adam Waldman, Chief Commercial Officer, explained that adding a quarterly subcutaneous option for BRIUMVI can more than double its peak sales opportunity. This new formulation allows TG Therapeutics to capture patients who prefer home administration, expanding its presence in the anti-CD20 market. The company plans to simplify initiation by combining two separate infusions into a single session, enhancing convenience for patients and medical centers, thereby creating demand tailwinds in the second half of 2027.

3. Long-Term Potential: Waldman also discussed the clinical trials exploring progressive MS and the substantial patent protection extending into the mid-2040s. With $557 million in cash and investments, TG Therapeutics maintains financial flexibility to fund pipeline progress alongside share repurchases. The CEO emphasized the company's confidence in BRIUMVI's long-term growth potential, confident in its ability to create value through scientific innovation, disciplined execution, and thoughtful investments.